Distinct Neuropsychological Mechanisms May Explain Delayed-Versus Rapid-Onset Antidepressant Efficacy

Neuropsychopharmacology

Volumn 40, Issue 9, 2015, Pages 2165-2174

  Stuart, Sarah A ^a   Butler, Paul ^b   Munafò, Marcus R ^a   Nutt, David J ^c   Robinson, Emma S J ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b PFIZER INC   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

KETAMINE; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; VENLAFAXINE; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; ANTIDEPRESSANT AGENT; CANNABINOID RECEPTOR ANTAGONIST; CARBOLINE DERIVATIVE; PIPERIDINE DERIVATIVE; PYRAZOLE DERIVATIVE; RIMONABANT;

AFFECTIVE BIAS; AMYGDALOID NUCLEUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; ASSOCIATION; COGNITIVE BIAS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG INFUSION; DRUG MECHANISM; EXCITOTOXICITY; LEARNING; MALE; MEDIAL PREFRONTAL CORTEX; MENTAL STRESS; NEUROPSYCHOLOGY; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; REINFORCEMENT; REPEATED DRUG DOSE; ANIMAL; BRAIN; COMPLICATION; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; MOOD DISORDERS; PHYSIOLOGY; REACTION TIME;

ANIMALS; ANTIDEPRESSIVE AGENTS; ASSOCIATION LEARNING; BRAIN; CANNABINOID RECEPTOR ANTAGONISTS; CARBOLINES; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GABA ANTAGONISTS; KETAMINE; MALE; MOOD DISORDERS; PIPERIDINES; PYRAZOLES; RATS; REACTION TIME; REINFORCEMENT (PSYCHOLOGY); STRESS, PSYCHOLOGICAL; VENLAFAXINE HYDROCHLORIDE;

EID: 84937161708     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2015.59     Document Type: Article

References (36)

1. Abel KM, Allin MP, Kucharska-Pietura K, David A, Andrew C, Williams S et al (2003). Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study. Neuroreport 14: 387-391.
2. Balleine BW, Killcross S (2006). Parallel incentive processing: an integrated view of amygdala function. Trends Neurosci 29: 272-279.
3. Beck AT (1967). Depression: Clinical, Experimental, and Theoretical Aspects. New York: Hoeber Medical Division.
4. Blundell P, Hall G, Killcross S (2001). Lesions of the basolateral amygdala disrupt selective aspects of reinforcer representation in rats. J Neurosci 21: 9018-9026.
5. Cardinal RN, Parkinson JA, Hall J, Everitt BJ (2002). Emotion and motivation: the role of the amygdala, ventral striatum, and prefrontal cortex. Neurosci Biobehav Rev 26: 321-352.
6. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007). Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706-1713.
7. Elliott R, Zahn R, Deakin JF, Anderson IM (2011). Affective cognition and its disruption in mood disorders. Neuropsycho-pharmacology 36: 153-182.
8. Gotlib IH, Joormann J (2010). Cognition and depression: current status and future directions. Annu Rev Clin Psychol 6: 285-312.
9. Hamani C, Mayberg H, Stone S, Laxton A, Haber S, Lozano AM (2011). The subcallosal cingulate gyrus in the context of major depression. Biol Psychiatry 69: 301-308.
10. Hamilton JP, Siemer M, Gotlib IH (2008). Amygdala volume in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Mol Psychiatry 13: 993-1000.
11. Harmer CJ (2008). Serotonin and emotional processing: does it help explain antidepressant drug action? Neuropharmacology 55: 1023-1028.
12. Harmer CJ, Goodwin GM, Cowen PJ (2009a). Why do antidepres-sants take so long to work? A cognitive neuropsychological model of antidepressant drug action. Br J Psychiatry 195: 102-108.
13. Harmer CJ, O'Sullivan U, Favaron E, Massey-Chase R, Ayres R, Reinecke A et al (2009b). Effect of acute antidepressant administration on negative affective bias in depressed patients. Am J Psychiatry 166: 1178-1184.
14. Herman JP, Cullinan WE (1997). Neurocircuitry of stress: central control of the hypothalamo-pituitary-adrenocortical axis. Trends Neurosci 20: 78-84.
15. Homayoun H, Moghaddam B (2007). NMDA receptor hypofunc-tion produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci 27: 11496-11500.
16. Horder J, Cowen PJ, Di Simplicio M, Browning M, Harmer CJ (2009). Acute administration of the cannabinoid CB1 antagonist rimonabant impairs positive affective memory in healthy volunteers. Psychopharm. (Berl) 205: 85-91.
17. Kessler RC (1997). The effects of stressful life events on depression. Annu Rev Psychol 48: 191-214.
18. Leppänen J (2006). Emotional information processing in mood disorders: a review of behavioral and neuroimaging findings. Curr Opin Psychiatry 19: 34-39.
19. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M et al (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329: 959-964.
20. Mathews DC, Zarate CA (2013). Current status of ketamine and related compounds for depression. J Clin Psychiatry 74: 516-517.
21. Moghaddam B, Adams B, Verma A, Daly D (1997). Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17: 2921-2927.
22. Morgan CJ, Mofeez A, Brandner B, Bromley L, Curran HV (2004). Acute effects of ketamine on memory systems and psychotic symptoms in healthy volunteers. Neuropsychopharmacology 29: 208-218.
23. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B (2007). Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 370: 851-858.
24. Paxinos G, Watson C (1998). The Rat Brain in Stereotaxic Coordinates4th edn.Academic: San Diego, London.
25. Pringle A, Browning M, Cowen PJ, Harmer CJ (2011). A cognitive neuropsychological model of antidepressant drug action. Prog Neuropsychopharmacol Biol Psychiatry 35: 1586-1592.
26. Ressler KJ, Mayberg HS (2007). Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci 10: 1116-1124.
27. Ribeiro PO, Rodrigues PC, Valentim AM, Antunes LM (2013). A single intraperitoneal injection of ketamine does not affect spatial working, reference memory or neurodegeneration in adult mice: A prospective animal study. Eur J Anaesthesiol 30: 618-626.
28. Roiser JP, Elliott R, Sahakian BJ (2012). Cognitive mechanisms of treatment in depression. Neuropsychopharmacology 37: 117-136.
29. Roozendaal B, Koolhaas JM, Bohus B (1997). The role of the central amygdala in stress and adaption. Acta Physiol Scand Suppl 640: 51-54.
30. Rumsfeld JS, Nallamothu BK (2008). The hope and fear of rimonabant. JAMA 299: 1601-1602.
31. Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reed LJ et al (2012). Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psycho-pathology. Mol Psychiatry 17: 664-665.
32. Stuart SA, Butler P, Munafò MR, Nutt DJ, Robinson ES (2013). A translational rodent assay of affective biases in depression and antidepressant therapy. Neuropsychopharmacology 38: 1625-1635.
33. Victor TA, Furey ML, Fromm SJ, Ohman A, Drevets WC (2010). Relationship between amygdala responses to masked faces and mood state and treatment in major depressive disorder. Arch Gen Psychiatry 67: 1128-1138.
34. Victor TA, Furey ML, Fromm SJ, Öhman A, Drevets WC (2013). Changes in the neural correlates of implicit emotional face processing during antidepressant treatment in major depressive disorder. Int J Neuropsychopharmacol 16: 2195-2208.
35. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B et al (2011). The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21: 655-679.
36. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA et al (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856-864.